EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA's corporate website and accessibility

Information on the website’s relaunch and discussion on the challenges of web accessibility

Patient and Consumer Working Party / Healthcare Professional Working Party and all eligible organisations meeting

15 November 2023

Presented by Christopher Gadd, Head of Online Communication

An agency of the European Union

Today's discussion

- **Relaunch of EMA's corporate website**
  - Presentation
    - What's changing
    - What's staying the same
    - Plans for 2024 and beyond
  - *Questions and answers* 
- **Challenges of web accessibility**
  - Presentation: Accessibility on EMA's corporate website
  - *Discussion: accessibility challenges and solutions* 

Join at

slido.com

#web123

Passcode: **web123**

Relaunch of EMA’s corporate website

EMA corporate website: ema.europa.eu

EMA's **main communication channel**

- Information and news on medicines
- Information on who we are and what we do
- Guidance for pharmaceutical industry

Large, **highly used** website:

- More than 1,000,000 visitors per month
- 133,000 page views per day
- 24,000 downloads per day
- 90% search engine optimisation score

Join at
slido.com
#web123
Passcode: web123

Website rebuild in Drupal 10

Go-live: 5 December 2023
- Migrating all content 'as is'
- Easier to move around website
- Upholding EMA's business needs



Post-go-live: February – December 2024
- Improvement of search interfaces, content subscription service etc.
- Accessibility testing

slido.com
#web123
Passcode: web123

Abevmy

bevacizumab

Medicine Human

Share RSS

Authorised
This medicine is authorised for use in the European Union

Page contents

Overview

Abevmy is a cancer medicine that is used to treat adults with the following cancers:

- cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
- breast cancer that has spread to other parts of the body;
- a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Abevmy can be used in non-small cell lung cancer unless the cancer originates in cells called squamous cells;
- cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
- cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb, and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment;
- cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or has spread to other parts of the body.

Abevmy is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work.

Abevmy is a 'biosimilar medicine'. This means that Abevmy is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Abevmy is Avastin. For more information on biosimilar medicines, see here.

Abevmy contains the active substance bevacizumab.

What’s staying

Homepage

All URLs will work

Web pages, documents & videos

What’s changing

Simple medicine search

Join at
slido.com
#web123
Passcode: web123

Medicines

Select type of medicine

Medicines for human use | Medicines for veterinary use | Herbal products | All

Search by name or active substance

My search term Search

Evaluating and supervising medicines for the benefit of public and animal health

The European Medicines Agency (EMA) facilitates development and access to medicines for countries within the European Union (EU). EMA evaluates applications for marketing authorisation, monitors, the safety of medicines across their lifecycle and provides information to healthcare professionals and patients. The medicines included in our work include medicines for human use, medicines for veterinary use and herbal medicines.

Our latest information on medicines, news and events for these therapeutic areas

HIV and AIDS

Lorem ipsum dolor sit amet, consectetur

Cancer

Lorem ipsum dolor sit amet, consectetur

Cardiovascular diseases

Lorem ipsum dolor sit amet, consectetur

What's staying

- Homepage
- All URLs will work
- Web pages, documents & videos

What's changing

- Simple medicine search
- Navigation: breadcrumbs
- Committee & expert information

2024 and beyond

- Content subscription
- Improved search
- Technical improvements (accessibility)

Challenges of web accessibility

Join at
slido.com
#web123
Passcode: web123

W3C Recommendation

TABLE OF CONTENTS

Web Content Accessibility Guidelines (WCAG) 2.2

W3C Recommendation 05 October 2023

▼ **More details about this document**

This version:
https://www.w3.org/TR/2023/REC-WCAG22-20231005/

Latest published version:
https://www.w3.org/TR/WCAG22/

Latest editor's draft:
https://w3c.github.io/wcag/guidelines/22/

History:
https://www.w3.org/standards/history/WCAG22/
Commit history

Implementation report:
https://www.w3.org/WAI/WCAG22/implementation-report/

Previous Recommendation:
https://www.w3.org/TR/WCAG21/

Editors:
Alastair Campbell (Nomensa)
Chuck Adams (Oracle)
Rachael Bradley Montgomery (Library of Congress)
Michael Cooper (W3C)
Andrew Kirkpatrick (Adobe)

Feedback:
GitHub w3c/wcag (pull requests, new issue, open issues)

Accessibility on EMA's corporate website

- All EMA websites conform to **WCAG 2.2 level AA**
- Increasing **focus** on accessibility on corporate website
  - Webteam staff trained in accessibility
  - Screening for issues using Siteimprove (quality-assurance tool)
  - Checking new website using screen readers
- Manual **testing** of accessibility planned for 2024
  - Contractors with cognitive and visual impairments
- **Multidisciplinary** challenge
  - Full implementation complex: many internal processes implicated

Siteimprove

Join at
slido.com
#web123
Passcode: web123

Join at

slido.com

#web123

Passcode: **web123**

Any questions?

Further information

Write to newwebsite@ema.europa.eu

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Telephone +31 (0)88 781 6000
Send us a question Go to www.ema.europa.eu/contact

Abevmy

bevacizumab

Medicine Human

Share RSS

Authorised
This medicine is authorised for use in the European Union

Page contents

Overview

Abevmy is a cancer medicine that is used to treat adults with the following cancers:

- cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
- breast cancer that has spread to other parts of the body;
- a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Abevmy can be used in non-small cell lung cancer unless the cancer originates in cells called squamous cells;
- cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
- cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb, and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment;
- cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or has spread to other parts of the body.

Abevmy is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work.

Abevmy is a 'biosimilar medicine'. This means that Abevmy is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Abevmy is Avastin. For more information on biosimilar medicines, see here.

Abevmy contains the active substance bevacizumab.

How is Abevmy used?

How does Abevmy work?

What benefits of Abevmy have been shown in studies?

What are the risks associated with Abevmy?

Why is Abevmy authorised in the EU?

What measures are being taken to ensure the safe and effective use of Abevmy?

Other information about Abevmy

European Immunization Week 2023

Share

18 September 2023

Statement by Executive Director Emer Cooke: Routine vaccination matters! Every dose counts to stay protected.

News | Human

Page contents

This year, European Immunization Week, marked between 23 and 29 April, reminds us about the importance of timely routine vaccination and why we need to catch up on any missed or postponed vaccines and booster doses.

Several routine vaccines are available for all age groups – young children, teenagers, adults and elderly – to protect us from dangerous diseases like **measles**, **rubella**, **hepatitis** or **meningitis**, just to name a few. The disruptions caused by **COVID-19** in healthcare and in our personal lives have led to serious delays in getting routine vaccines, causing significant consequences in our communities across the European Union (EU).

> The European Immunization Week should be a call to action for every European citizen.
>
> — Emer Cooke

We cannot stay passive in the face of threats like measles, **polio**, **diphtheria** or **tetanus**.

We must not fail to keep up with immunization against rubella. Unvaccinated pregnant women who get rubella are at high risk of miscarriage or congenital rubella syndrome in their babies.

We cannot fall behind in vaccinating teenagers and children aged 9-14 against **human papillomavirus** (HPV). The infection with this virus in boys and girls can lead to some cancers later in life, when they are adult women and men.

Finally, we must protect the elderly. They are at high risk of hospitalisation or death when they catch a virus.

Resources

Info-cards



UNICEF immunization data

Getting measles vaccination back on track

External links

- European Immunization Week 2023 - European Centre for Disease Prevention and Control
- European Immunization Week 2023 - World Health Organization
- Immunization coverage - UNICEF
- Getting measles vaccination back on track - European Commission
- New data indicates declining confidence in childhood vaccines of up to 44 percentage points in some countries during the COVID-19 pandemic - UNICEF report
- European Vaccination Information Portal (EVIP)

Media

Share

On this page, we highlight information of particular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union. For more information and details relevant for media, see our News & events section. For enquiries from media, please contact the EMA press office.

Featured information

EMA communication activities

We asked stakeholders for feedback on our communication activities in a survey in 2022 and captured the results in a newly-published report. The findings help us set targets, address areas for improvement and measure progress. We thank all respondents for their feedback.

Survey

EU agencies promoting a One Health approach

EMA and other scientific EU agencies responsible for human, animal health and environmental protection have established a task force to coordinate activities and share information, promoting a joined-up One Health approach. A paper is available containing more details.

OneHealth

2022 annual report

Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency's main activities in 2022. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.

Annual report

Human medicines: highlights of 2022

In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active substance which had never been authorised in the European Union before. These included two vaccines and two treatments for COVID-19.

Human medicines

News for media

EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep

EMA's human medicines committee (CHMP) has recommended not renewing the conditional marketing authorisation for Blenrep (belantamab mafodotin), a medicine used to treat multiple myeloma (a cancer of the bone marrow).

18 September 2023

Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies

EMA's human medicines committee (CHMP) has recommended not renewing the conditional marketing authorisation for Blenrep (belantamab mafodotin), a medicine used to treat multiple myeloma (a cancer of the bone marrow).

18 September 2023

SEE ALL NEWS →

Data highlights : Human medicines in 2022

704

Scientific advice requests received

47 of these were for COVID-19 medicines or vaccines

40

PRIME recommenations adopted

45 eligibility requests were also received

100

Applications for initial evaluation received

89 positive opinions, 16 withdrawn applications, 3 negative opinions